Literature DB >> 17101928

Maintaining adherence and retention in dementia prevention trials.

Steven T DeKosky1.   

Abstract

Incidence and prevalence of Alzheimer Disease (AD) will rise in a accelerating fashion through the middle of the 21st century. Increased understanding of the pathological cascades in AD, and the knowledge that the initial brain changes begin years prior to clinical manifestations, have led to initiation of trials to prevent AD. With many of the designs being used or contemplated, prevention trials will involve repeated cognitive and functional assessments over years, require cooperation and collaboration of both the subject and a partner or proxy, and represent a substantial time and resource investment by the research team. Compliance with the study regimen and adherence to the protocol are thus major foci for study efficiency and success. In this section methods by which compliance and adherence can be optimized are discussed. Research on the effectiveness of these and other evolving methods will be of help in assuring success of such large scale studies in the future.

Entities:  

Mesh:

Year:  2006        PMID: 17101928     DOI: 10.1212/wnl.67.9_suppl_3.s14

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  7 in total

1.  Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative.

Authors:  Joshua D Grill; Lijie Di; Po H Lu; Cathy Lee; John Ringman; Liana G Apostolova; Nicole Chow; Omid Kohannim; Jeffrey L Cummings; Paul M Thompson; David Elashoff
Journal:  Neurobiol Aging       Date:  2012-04-13       Impact factor: 4.673

Review 2.  Analysis of start-up, retention, and adherence in ALS clinical trials.

Authors:  Nazem Atassi; Padmaja Yerramilli-Rao; Jackie Szymonifka; Hong Yu; Marianne Kearney; Daniela Grasso; Jing Deng; Mark Levine-Weinberg; Jordan Shapiro; Alexandra Lee; Lucia Joseph; Eric A Macklin; Merit E Cudkowicz
Journal:  Neurology       Date:  2013-09-04       Impact factor: 9.910

3.  Why They Stay: Understanding Research Participant Retention in Studies of Aging, Cognitive Impairment and Dementia.

Authors:  Judith Neugroschl; Mary Sano; Xiaodong Luo; Margaret Sewell
Journal:  J Gerontol Geriatr Res       Date:  2014-10

4.  Near-infrared spectroscopy (NIRS) and vagus somatosensory evoked potentials (VSEP) in the early diagnosis of Alzheimer's disease: rationale, design, methods, and first baseline data of the Vogel study.

Authors:  Thomas Polak; Martin J Herrmann; Laura D Müller; Julia B M Zeller; Andrea Katzorke; Matthias Fischer; Fabian Spielmann; Erik Weinmann; Leif Hommers; Martin Lauer; Andreas J Fallgatter; Jürgen Deckert
Journal:  J Neural Transm (Vienna)       Date:  2017-09-01       Impact factor: 3.575

Review 5.  The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.

Authors:  Napatkamon Ayutyanont; Jessica B S Langbaum; Suzanne B Hendrix; Kewei Chen; Adam S Fleisher; Michel Friesenhahn; Michael Ward; Camilo Aguirre; Natalia Acosta-Baena; Lucìa Madrigal; Claudia Muñoz; Victoria Tirado; Sonia Moreno; Pierre N Tariot; Francisco Lopera; Eric M Reiman
Journal:  J Clin Psychiatry       Date:  2014-06       Impact factor: 4.384

6.  Adherence/Retention Alzheimer's Prevention Initiative Colombia Plan.

Authors:  Silvia Rios-Romenets; Natalia Acosta-Baena; Liliana Lopez; Lucia Madrigal-Zapata; Helen Street; Laura Jakimovich; Jessica B Langbaum; William Cho; Eric M Reiman; Pierre N Tariot; Francisco Lopera
Journal:  Alzheimers Dement (N Y)       Date:  2018-07-14

7.  Assessing compliance: active versus inactive trainees in a memory intervention.

Authors:  Dana K Bagwell; Robin L West
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.